The Efficacy and Safety of 4-n-butylresorcinol 0.1% Cream for the Treatment of Melasma: A Randomized Controlled Split-face Trial
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Melasma is a common acquired symmetrical hypermelanosis that occurs on sun-exposed areas, and it is frequently observed among women. Various treatment modalities have been tried, but none are completely satisfactory. 4-n-butylresorcinol, which is a resorcinol derivative that has an inhibitory effect on both tyrosinase and tyrosinase-related protein-1, was introduced in 1995 and it has received increasing attention as a new hypopigmenting agent. However, the hypopigmenting effect of 4-n-butylresorcinol in human subjects has only been shown in a few studies. Objective: The aim of this study was to investigate the hypopigmenting efficacy and safety of 4-n-butylresorcinol 0.1% cream for the treatment of melasma. Methods: Twenty patients with melasma were enrolled to this randomized,double-blind, vehicle-controlled, split-face comparative study. The patients were instructed to apply 4-n-butylresorcinol 0.1% cream or vehicle to each side of the face twice daily for 8 weeks. Mexameter measurements were performed along with photography at baseline, 4 weeks and 8 weeks. Adverse events were observed and recorded throughout the study. Results: All the patients completed the study. Mexameter measurements demonstrated that the melanin index of the treated side showed a significant decrease when compared with that of the vehicle-treated side after 4 weeks (p=0.006) and after 8 weeks (p＜0.0005). All the adverse reactions were mild and transient. Conclusion: 4-n-butylresorcinol 0.1% cream showed rapid efficacy and it was well tolerated when used for the treatment of melasma. (Ann Dermatol 22(1) 21∼25, 2010)
Abstract
Background: Melasma is a common acquired symmetrical hypermelanosis that occurs on sun-exposed areas, and it is frequently observed among women. Various treatment modalities have been tried, but none are completely satisfactory. 4-n-butylresorcinol, which is a resorcinol derivative that has an inhibitory effect on both tyrosinase and tyrosinase-related protein-1, was introduced in 1995 and it has received increasing attention as a new hypopigmenting agent. However, the hypopigmenting effect of 4-n-butylresorcinol in human subjects has only been shown in a few studies. Objective: The aim of this study was to investigate the hypopigmenting efficacy and safety of 4-n-butylresorcinol 0.1% cream for the treatment of melasma. Methods: Twenty patients with melasma were enrolled to this randomized,double-blind, vehicle-controlled, split-face comparative study. The patients were instructed to apply 4-n-butylresorcinol 0.1% cream or vehicle to each side of the face twice daily for 8 weeks. Mexameter measurements were performed along with photography at baseline, 4 weeks and 8 weeks. Adverse events were observed and recorded throughout the study. Results: All the patients completed the study. Mexameter measurements demonstrated that the melanin index of the treated side showed a significant decrease when compared with that of the vehicle-treated side after 4 weeks (p=0.006) and after 8 weeks (p＜0.0005). All the adverse reactions were mild and transient. Conclusion: 4-n-butylresorcinol 0.1% cream showed rapid efficacy and it was well tolerated when used for the treatment of melasma. (Ann Dermatol 22(1) 21∼25, 2010)
참고문헌 (13)
- Hearing VJ, "Enzymatic control of pigmentation in mammals", FASEB J, 5, pp.2902~2909 (1991)
- Kobayashi T, "Tyrosinase related protein 1(TRP1)functions as a DHICA oxidase in melanin biosynthesis", EMBO J, 13, pp.5818~5825 (1994)
- "J Dermatol Sci", 1995, 88~
- Tasaka K, "Effects of certain resorcinol derivatives on the tyrosinase activity and the growth of melanoma cells", Methods Find Exp Clin Pharmacol, 20, pp.99~109 (1998)
- Katagtri T, "Novel melanogenic enzymes inhibitor for controlling hyperpigmentation", 20th IFSCC International Congress, pp.1~11 (1998)
- Shimizu K, "Inhibition of tyrosinase by flavonoids,stilbenes and related 4-substituted resorcinols:structure-activity investigations", Planta Med, 66, pp.11~15 (2000)
- Kim DS, "Inhibitory effects of 4-n-butylresorcinol on tyrosinase activity and melanin synthesis", Biol Pharm Bull, 28, pp.2216~2219 (2005)
- Akasaka T, "Topically applied 0.3% 4-n-butylresorcinol decreases pigmentation after laser therapy", Environ Dermatol, 9, pp.11~15 (2002)
- Researching committee of Rucinol(R), "The study on the efficacy of Rucinol(R)(4-n-butylresorcinol)in chloasma", Nishinihon J Dermatol, 61, pp.813~819 (1999)
- Khemis A, "Evaluation of efficacy and safety of rucinol serum in patients with melasma:a randomized controlled trial", Br J Dermatol, 156, pp.997~1004 (2007)
- Cassano N, "Peeling agents:toxicological and allergological aspects", J Eur Acad Dermatol Venereol, 13, pp.14~23 (1999)
- Long CC, "The finger-tip unit--a new practical measure", Clin Exp Dermatol, 16, pp.444~447 (1991)
- Clarys P, "Skin color measurements:comparison between three instruments:the Chromameter(R),the DermaSpectrometer(R)and the Mexameter(R)", Skin Res Technol, 6, pp.230~238 (2000)